Sudeep Pharma Limited has reported its audited consolidated financial results for the fourth quarter and financial year ended March 31, 2026. The results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 21, 2026, and subsequently published in Business Standard and Vadodara Samachar on May 22, 2026. The company's board recommended a final dividend of ₹1.50 per equity share, subject to shareholder approval at the upcoming Annual General Meeting. Additionally, the board appointed M/s. Chetan Gandhi & Associates as Cost Auditor and M/s H M Mehta & Associates as Secretarial Auditor for the financial year 2026-27.

Q4 Consolidated Financial Performance

For the fourth quarter ended March 31, 2026, Sudeep Pharma reported consolidated total income from operations of ₹18,876.34 lakhs, compared to ₹16,130.57 lakhs in the same period last year. Net profit after tax for the quarter stood at ₹4,853.82 lakhs, up from ₹4,418.57 lakhs year-on-year. Total comprehensive income for the quarter came in at ₹5,470.10 lakhs, compared to ₹4,336.86 lakhs in Q4 FY25. Earnings per share (basic and diluted) for the quarter were ₹4.38, against ₹4.07 in the corresponding prior-year period.

Full Year Consolidated Financial Highlights

For the full financial year ended March 31, 2026, Sudeep Pharma reported consolidated total income from operations of ₹67,084.34 lakhs, a significant increase from ₹51,132.83 lakhs in the previous year. Net profit after tax for the year rose to ₹17,428.47 lakhs from ₹13,872.92 lakhs, reflecting a year-on-year growth of approximately 26%. Total comprehensive income for the full year stood at ₹17,305.95 lakhs, compared to ₹13,709.41 lakhs in FY25. Equity share capital as at March 31, 2026 stood at ₹1,129.49 lakhs, while reserves (excluding revaluation reserve) were ₹87,204.31 lakhs. Annual earnings per share (basic and diluted) were ₹15.50, up from ₹12.79 in FY25. The company completed an Initial Public Offering (IPO) during the year, listing its shares on the NSE and BSE on November 28, 2025.

Standalone Financial Performance

On a standalone basis, total income from operations for Q4 FY26 was ₹8,978.62 lakhs, compared to ₹10,794.93 lakhs in Q4 FY25. Standalone net profit after tax for the quarter stood at ₹2,576.56 lakhs, against ₹3,313.56 lakhs in the year-ago period. For the full year, standalone total income from operations grew to ₹37,700.94 lakhs from ₹36,510.73 lakhs, while standalone net profit after tax rose to ₹10,758.07 lakhs from ₹9,574.77 lakhs.

Strategic Capacity Expansion for FY27

Sudeep Pharma has outlined an ambitious capacity expansion roadmap for FY27 across its key business segments. In the Pharma, Food, and Nutrition segment, the company is targeting a total capacity of 86,200 MT, supported by a 51,200 MT greenfield project currently underway. The Specialty Ingredients segment capacity is maintained at 37,500 MT, while Phase 1 of the Battery Materials facility — focused on Iron Phosphate production — is being launched with a starting capacity of 25,000 MT.

The following table summarises the planned capacity targets across segments:

The greenfield project at Nandesari has completed the Internal Validation and Qualification Process, with Customer Validation Trials currently ongoing. The groundbreaking ceremony for the Battery Materials Facility in Dahej was successfully conducted on January 23, 2026, with Phase 1 construction currently underway and expected to be completed by early CY27.

Sudeep Pharma Limited has intimated that its officials will participate in upcoming investor conferences scheduled for May 28 and June 8, 2026. The meetings are being held pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Investor Conference Schedule

The company management will engage in one-on-one and group meetings with analysts and institutional investors. The discussions will be based solely on publicly available information, and no unpublished price sensitive information (UPSI) will be shared.

Conference Details

The first event is the 360 ONE Capital (B&K) 16th Annual Investor Conference, titled TRINITY INDIA 2026, set to take place on May 28. Following this, the company will attend the ICICI Securities India Investor Conference, themed "India Rising: The Next Chapter," on June 8. Both events will be conducted physically at the Grand Hyatt in Mumbai.

The company noted that changes to the schedule may occur due to exigencies on the part of the host or the company. Dimple Mehta, Company Secretary & Compliance Officer, signed the intimation on May 23, 2026.